<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[john maas Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/john+maas.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to john maas]]></description>
	<s:counts start="0" returned="20" found="85" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Pharma Roundup: Lilly and Prasugrel, Roche and Genentech, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000780/pharma-roundup-lilly-and-prasugrel-roche-and-genentech-and-more/]]></link>
		<description><![CDATA[Prasugrel's FDA approval looks closer -- Prasugrel, the blood thinner on which Lilly is pinning so much hope, got a boost in a newly-published FDA document stating that "the Division recommends approval of prasugrel." The briefing is meant to sway the outside committee that will convene next week to advise...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 30 Jan 2009 16:40:38 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/prasugrel.html"><![CDATA[Prasugrel]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Glaxo's $400 Million Penalty, Cuts at AstraZeneca, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000751/pharma-roundup-glaxos-400-million-penalty-cuts-at-astrazeneca-and-more/]]></link>
		<description><![CDATA[GSK to lose $400 million on legal challenge -- Legal action against GlaxoSmithKline, stemming from the state of Colorado's allegations of improper marketing on nine top products, will cost $400 million, the company has announced. The charge will appear in the fourth quarter results due in February. [Source: WSJ Health...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 29 Jan 2009 17:33:10 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/blogging.html"><![CDATA[Blogging]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[Internet]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">AZN,NVS</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Roche Insulates Against Suitors, Bristol Faces Problems, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000728/pharma-roundup-roche-insulates-against-suitors-bristol-faces-problems-and-more/]]></link>
		<description><![CDATA[Roche's founding family moves to block acquisitions -- In today's feverish climate of M&A speculation, the descendants of Roche's founder indefinitely extended their majority voting stake in the company. This will make it more difficult for a competitor, like Novartis (which already owns 33 percent of Roche), to swoop in...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 28 Jan 2009 17:18:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/blogging.html"><![CDATA[Blogging]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[Internet]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer, Wyeth, Amgen, Bristol, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000708/pharma-roundup-pfizer-wyeth-amgen-bristol-and-more/]]></link>
		<description><![CDATA[Pfizer and Wyeth: how many jobs are actually being cut? -- The Health Blog provides a run-down on the various figures that are being tossed around, from 18,000 to 26,000. Their estimate with the math to back it up is 19,425 from the combined company, with at least 8,190 coming...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 27 Jan 2009 17:49:26 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">AMGN,PFE,WYE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer and Wyeth, Best Coverage]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000677/pharma-roundup-pfizer-and-wyeth-best-coverage/]]></link>
		<description><![CDATA[Today's big pharma news is, of course, that Pfizer is buying Wyeth a story broken by the Wall Street Journal last week for $60 billion. The deal has seen a flurry of analysis and commentary from the blogosphere; today's Roundup highlights the best content out there.    First,...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 26 Jan 2009 17:27:52 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">PFE,WYE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer and Wyeth, GlaxoSmithKline Overseas, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000632/pharma-roundup-pfizer-and-wyeth-glaxosmithkline-overseas-and-more/]]></link>
		<description><![CDATA[Pfizer and Wyeth: ramifications for the industry -- In a much-reported bit of news, Pfizer and Wyeth have been in merger talks for month, although there's no reason to believe the deal will necessarily go through. BNET's Jim Edwards has the details on what that would mean for the two...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 23 Jan 2009 16:26:23 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">DNA,GSK,PFE,WYE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer and the Rat, Johnson & Johnson in Europe, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000626/pharma-roundup-pfizer-and-the-rat-johnson-johnson-in-europe-and-more/]]></link>
		<description><![CDATA[Pfizer's gruesome new anti-counterfeit campaign -- In the U.K., Pfizer has rolled out a new TV ad that warns consumers against the dangers of counterfeit drugs. The nauseating image of a man pulling a rat from his mouth intends to educate consumers about the dangerous substances like rat poison which...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 22 Jan 2009 16:32:29 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/europe.html"><![CDATA[Europe]]></category>
		<category domain="http://resources.bnet.com/topic/firms.html"><![CDATA[Firms]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">JNJ,PFE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Johnson & Johnson, Abbott, Forest, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000621/pharma-roundup-johnson-johnson-abbott-forest-and-more/]]></link>
		<description><![CDATA[An unhappy wind blows through Johnson & Johnson -- Patent expirations are taking their toll on the drug giant, which has seen profits slip and year-over-year sales drop 11 percent. Analysts predict an acquisition. [Source: Forbes, via Corey Nahman]    Abbott's diversification brings financial health -- The yin...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 21 Jan 2009 16:48:48 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer Examined; Merck, UPS, and Wholesalers; and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000614/pharma-roundup-pfizer-examined-merck-ups-and-wholesalers-and-more/]]></link>
		<description><![CDATA[Pfizer's dangerous tendency to save management instead of its operations -- ... is one of the company's problems, according to some commentary in this analysis of the Biggest Pharma. Yes, it is the largest, but that certainly doesn't immunize Pfizer against the tremendous pressures of the current climate -- especially...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 20 Jan 2009 16:39:41 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/united+parcel+service+of+america+inc..html"><![CDATA[United Parcel Service Of America Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/wholesaler.html"><![CDATA[Wholesaler]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">UPS</category>
		<category domain="tickers">MRK,NDAQ,PFE,UPS</category>
	</item>
	<item>
		<title><![CDATA[Authenticity â€” What Voters (and Consumers) Really Want | HBR IdeaCast]]></title>
		<link><![CDATA[http://blogs.bnet.com/intercom/?p=1936]]></link>
		<description><![CDATA[  Corporations and presidential campaigns both have a tough sell where authenticity is concerned, but striking a resonant chord with consumers brings sales and votes. In this podcast, Joseph Pine and James Gilmore extract lessons from the 2008 presidential race to illustrate the three "M's" of inauthenticity, the difference...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 20 Jan 2009 10:21:13 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/authenticity.html"><![CDATA[Authenticity]]></category>
		<category domain="http://resources.bnet.com/topic/podcasts.html"><![CDATA[Podcasts]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[Internet]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Novartis Flu Contract, Roche Leads Cancer, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000609/pharma-roundup-novartis-flu-contract-roche-leads-cancer-and-more/]]></link>
		<description><![CDATA[U.S. government awards $486 million flu contract to Novartis -- The deal funds a Novartis plant to be built in Holly Springs, North Carolina; the plant will employee 300 people and will be capable of producing 150 million doses of flu vaccine within six months in the event of a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 16 Jan 2009 16:23:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">DNA,NVS</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Lilly's Zyprexa Settlement; Cuts at Pfizer, Roche; and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000608/pharma-roundup-lillys-zyprexa-settlement-cuts-at-pfizer-roche-and-more/]]></link>
		<description><![CDATA[Lilly's Zyprexa settlment is biggest ever; Pfizer may cut 2,400; Roche cuts 780; Novartis' Ebeling on the future of pharma. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 15 Jan 2009 16:19:14 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/settlement.html"><![CDATA[Settlement]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer Sells Experimental Drugs, Genentech Tight-Lipped on Roche, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000606/pharma-roundup-pfizer-sells-experimental-drugs-genentech-tight-lipped-on-roche-and-more/]]></link>
		<description><![CDATA[Pfizer pawns off irrelevant drugs -- Pfizer just sold rights to over 100 experimental drugs. The closeout comes on the heels of the company's autumn promise to streamline R&D; the ditched treatments focus on conditions Pfizer will no longer study, like obesity and high cholesterol. [Source: WSJ Health Blog] ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 14 Jan 2009 16:24:39 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">DNA,PFE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Merck's Gardasil Exec, Elan's Future, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000595/pharma-roundup-mercks-gardasil-exec-elans-future-and-more/]]></link>
		<description><![CDATA[Merck shuffles Gardasil exec; Elan plans its future; Deerfield really wants all of Nitromed; an anecdotal barometer of biotech's health. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 13 Jan 2009 15:37:37 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Roche Acknowledges Genentech "Fear," GSK Cuts Ads, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000590/pharma-roundup-roche-acknowledges-genentech-fear-gsk-cuts-ads-and-more/]]></link>
		<description><![CDATA[Roche exec talks Genentech's "fears," Glaxo slashes DTC ad spend, Abbott buys LASIK device company, Deepak Chopra's editorial examined. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 12 Jan 2009 17:01:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/wall+street+journal.html"><![CDATA[Wall Street Journal]]></category>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Cephalon's Strategy, GSK: "No Big M&A," and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000580/pharma-roundup-cephalons-strategy-gsk-no-big-ma-and-more/]]></link>
		<description><![CDATA[Cephalon's winning business model -- Time and time again, Cephalon buys a drug for cheap and then gives it the resources to become a success, earning big money in the process -- 2009 revenue for the company should top $2 billion. Combined with "superior drug scouting" and "hyperaggressive marketing," it's...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 09 Jan 2009 17:07:19 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/m%2526a.html"><![CDATA[M&A]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vanderbilt+university.html"><![CDATA[Vanderbilt University]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">CEPH,JNJ</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Merck CEO Admits Failure, Lilly's New Zyprexa Delay, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000574/pharma-roundup-merck-ceo-admits-failure-lillys-new-zyprexa-delay-and-more/]]></link>
		<description><![CDATA[Merck CEO admits Merck's mistakes, Lilly's long-acting Zyprexa formulation delayed again by FDA, VC funding goes on, Actavis for sale by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 08 Jan 2009 16:41:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer's Lipitor Patent, Wyeth and Crucell, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000570/pharma-roundup-pfizers-lipitor-patent-wyeth-and-crucell-and-more/]]></link>
		<description><![CDATA[Court re-validates Pfizer's Lipitor patent; Wyeth wants to buy Crucell; new spin-off Facet cuts jobs; Merckle family to sell Ratiopharm. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 07 Jan 2009 15:33:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[Patent]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/crucell.html"><![CDATA[Crucell]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">PFE,WYE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Daiichi's Ranbaxy Write-Down, Merck's UPS Deal, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000562/pharma-roundup-daiichis-ranbaxy-write-down-mercks-ups-deal-and-more/]]></link>
		<description><![CDATA[Daiichi to lose $4 billion on Ranbaxy. UPS to run Merck distribution centers. Taro rejects Sun. U.S. prescription sales slump. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 06 Jan 2009 16:40:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/united+parcel+service+of+america+inc..html"><![CDATA[United Parcel Service Of America Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sun+microsystems+inc..html"><![CDATA[Sun Microsystems Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAVA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">UPS</category>
		<category domain="tickers">MRK,JAVA,UPS</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000555/pharma-roundup-pfizers-acquisition-plans-prasugrels-big-day-and-more/]]></link>
		<description><![CDATA[Pfizer wants acquisitions, big and small. Prasugrel has a date with the FDA. New Year's blog feature bonanza. Farewell, Pharmalot. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 05 Jan 2009 17:09:28 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/acquisition.html"><![CDATA[Acquisition]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/lilly.html"><![CDATA[Lilly]]></category>
		<category domain="http://resources.bnet.com/topic/pharmalot.html"><![CDATA[Pharmalot]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
</channel>
</rss>
